Hookipa Pharma (HOOK) AI Stock Analysis

• Market Cap: $15.92M
• Dividend Yield: N/A
• Average Volume (3M): 136.51K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.35
• Revenue Growth: -82.54%
• EPS Growth: -12.53%
• Country: US
• Employees: 82
• Sector: Healthcare
• Sector Strength: 46
• Industry: Biotechnology
• EPS (TTM): -1.23
• Shares Outstanding: 9,797,818
• 10 Day Avg. Volume: 78,320
• 30 Day Avg. Volume: 136,513
• PEG Ratio: 0.01
• Price to Book (P/B): 0.52
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.12
• Enterprise Value/Market Cap: -3.38
• Enterprise Value/Revenue: -0.35
• Enterprise Value/Gross Profit: -6.22
• Enterprise Value/Ebitda: 0.27
• 1Y Price Target: $2.00
• Price Target Upside: 53.85% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 44 Neutral
• Price Target: $1.50 ▲(15.38%Upside)

The overall stock score of 44.2 reflects significant financial challenges faced by Hookipa Pharma, characterized by zero revenue and persistent losses. Technical analysis provides mixed signals, and valuation metrics indicate potential risks due to negative earnings. These factors collectively suggest a cautious investment outlook with a need for strategic shifts to improve financial stability.

Positive Factors

M&A Activity

Poolbeg shareholders are expected to receive 0.03 shares of Hookipa for each Poolbeg share, resulting in approximately 55% of the equity of the combined entity.

Negative Factors

Financial Position

Hookipa had approximately $60M in cash, which is believed to be insufficient to support the company to realize meaningful value inflection points from its own pipeline.

Shareholder Dilution

Current Hookipa shareholders are expected to face significant dilution.

Hookipa Pharma Business Overview & Revenue Model

Company Description

Hookipa Pharma (HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies aimed at preventing and treating infectious diseases and cancers. The company leverages its proprietary arenavirus platform to engineer novel therapies that activate and amplify the immune system's response to target diseases. Hookipa's pipeline includes a range of product candidates designed to address unmet medical needs, with a strategic focus on advancing therapies through clinical trials to demonstrate safety and efficacy.

How the Company Makes Money

Hookipa Pharma generates revenue primarily through collaborations and partnerships with other pharmaceutical companies and institutions. These collaborations often involve upfront payments, milestone payments, and potential royalty payments upon successful commercialization of products. The company also seeks funding through government grants and research contracts to support the development of its proprietary technology and the advancement of its clinical pipeline. As a clinical-stage company, its revenue model is heavily reliant on these strategic partnerships and external funding sources until its product candidates receive regulatory approval and are commercialized.

Hookipa Pharma Financial Statement Overview

Summary

Hookipa Pharma faces substantial financial difficulties across its income statement, balance sheet, and cash flow. With zero revenue in the latest year and persistent losses, the company struggles with profitability and revenue generation. While leverage risk is low due to minimal debt, declining equity and cash flow challenges raise concerns over long-term financial health. Significant strategic changes are necessary to improve revenue, control costs, and stabilize cash flows to ensure sustainability.

Income Statement

Hookipa Pharma's income statement reveals a challenging financial performance with zero revenue in 2024, a significant decline from previous years. The gross profit margin is non-existent, and they have substantial negative EBIT and EBITDA margins. The net profit margin is also negative, reflecting ongoing losses. Revenue growth has been inconsistent, with a notable drop in the most recent year. The company's trajectory indicates financial instability and a need for strategic adjustments to improve revenue streams.

Balance Sheet

The balance sheet of Hookipa Pharma shows a moderate level of financial stability. The debt-to-equity ratio is low due to minimal debt, indicating low leverage risk. However, the return on equity is negative, driven by consecutive net losses. The equity ratio is satisfactory, suggesting a capital structure with a higher proportion of equity funding. Despite the low debt levels, the declining equity value and recurring losses raise concerns about long-term solvency and the need for improved operational performance.

Cash Flow

Cash flow analysis highlights significant challenges, with negative operating and free cash flows in 2024, further deteriorating from the previous year. The free cash flow to net income ratio and operating cash flow to net income ratio are adverse, reflecting cash outflows exceeding earnings. The free cash flow growth rate is negative, indicating a need for better cash management and operational efficiency. Overall, cash flow constraints pose a risk to sustaining operations without fresh capital infusions.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
9.35M	43.95M	20.13M	14.25M	18.45M	19.58M
	Gross Profit
8.65M	43.95M	16.58M	10.65M	13.81M	-33.55M
	EBIT
-80.44M	-51.45M	-97.69M	-73.16M	-81.67M	-53.28M
	EBITDA
-70.92M	-40.85M	-77.34M	-60.40M	-70.13M	-39.15M
	Net Income Common Stockholders
-73.31M	-43.50M	-81.58M	-64.92M	-75.67M	-44.08M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
40.28M	39.68M	117.10M	113.44M	66.91M	143.18M
	Total Assets
61.26M	82.55M	161.34M	170.45M	126.05M	187.82M
	Total Debt
596.00K	875.00K	6.56M	6.50M	10.63M	10.51M
	Net Debt
-39.68M	-38.81M	-110.54M	-106.94M	-56.29M	-132.67M
	Total Liabilities
27.18M	31.33M	71.48M	67.94M	36.45M	31.69M
	Stockholders Equity
34.08M	51.21M	89.86M	102.52M	89.59M	156.12M
Cash Flow		Free Cash Flow
-52.87M	-77.17M	-61.68M	-25.01M	-78.60M	-41.71M
	Operating Cash Flow
-52.77M	-76.98M	-57.52M	-20.00M	-66.02M	-39.34M
	Investing Cash Flow
-98.00K	-194.00K	-4.16M	-5.02M	-12.58M	-2.37M
	Financing Cash Flow
-1.14M	-1.28M	65.67M	72.27M	-235.00K	73.42M

Hookipa Pharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.30
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HOOK, the sentiment is Negative. The current price of 1.3 is below the 20-day moving average (MA) of 1.52, above the 50-day MA of 1.26, and below the 200-day MA of 2.32, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 40.97 is Neutral, neither overbought nor oversold. The STOCH value of 14.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HOOK.

Hookipa Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.24B	3.26	-44.35%	6.48%	16.78%	-0.10%
MBRX	44 Neutral	$8.24M	―	-214.79%	―	―	52.82%
HOOK	44 Neutral	$15.92M	―	-105.79%	―	-82.54%	-12.53%
PHGE	44 Neutral	$10.21M	―	-68.18%	―	―	45.24%
EQ	41 Neutral	$11.52M	―	-88.32%	―	-19.76%	-13.20%
CBIO	40 Underperform	$9.43M	―	11.62%	―	-100.00%	-0.58%
NXTC	36 Underperform	$12.66M	―	-63.94%	―	―	22.63%

Hookipa Pharma Corporate Events

Hookipa Pharma Sells Assets to Gilead Sciences

On May 21, 2025, Hookipa Pharma and its subsidiary entered into an Asset Purchase Agreement with Gilead Sciences to sell assets related to their HB-400 and HB-500 programs. The agreement includes a purchase price of up to $10 million, with $3 million payable at closing and the remainder contingent on a three-phase transfer plan. The transaction requires stockholder approval and involves customary conditions and indemnifications. Additionally, the collaboration agreement with Gilead will terminate upon closing, and the ongoing HB-500 trial will be wound down.

The most recent analyst rating on (HOOK) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Hookipa Pharma stock, see the HOOK Stock Forecast page.